Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 206,744 shares at $1.29 ($266K) on 2022-10-04, disclosed to the SEC on 2022-10-05.
Open-market purchase of $266k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.29 | 95,541 | $123K | 46.4% |
| 2 | $1.29 | 95,541 | $123K | 46.4% |
| 3 | $1.23 | 15,662 | $19K | 7.2% |
| Total | $1.29 avg | 206,744 | $266K | 100% |
| Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |
| OTLK | BUY | 2022-02-23 | $514K | — | Filing → |